PGP-4008 |
| Catalog No.GC44615 |
PGP-4008 est un inhibiteur spécifique de la glycoprotéine P (Pgp). Le PGP-4008 inhibe la croissance tumorale dans un modèle de tumeur solide de résistance multiple médiée par la Pgp syngénique murine lorsqu'il est administré en association avec la doxorubicine.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 365565-02-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
PGP-4008 is a selective inhibitor of P-glycoprotein (P-gp) that does not affect the activity of multidrug resistance-related protein 1 (MRP1). It is effective in vitro and, when delivered intraperitoneally, in vivo, inhibiting tumor growth when given with doxorubicin . PGP-4008 also enhances the ability of docetaxel to inhibit growth and drive apoptosis in ovarian cancer cells.
Average Rating: 5 (Based on Reviews and 37 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *